Volitionrx Ltd 8-K, filed Sep 2, 2026
Volitionrx Ltd (VNRX)
About this 8-K
Volitionrx Ltd filed this 8-K on September 2, 2026, reporting on events of August 27, 2026.
Items reported
- Item 3.02: Unregistered sale of equity
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of Incorporation) |
| File Number) |
| Identification Number) |
(Address of principal executive offices and zip code)
+1 (
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed from last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) |
| Name of Each Exchange on which Registered | |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.02 Unregistered Sales of Equity Securities
As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”), senior secured convertible promissory notes in the original principal amounts of $7,500,000 and $2,400,000. In connection with its obligations under such notes, (a) on August 27, 2026 the Company issued to Lind an aggregate of 712,328 shares of common stock to satisfy a $260,000 conversion obligation, (b) on August 27, 2026 the Company issued to Lind an aggregate of 520,547 shares of common stock to satisfy a $190,000 conversion obligation, (c) on August 31, 2026 the Company issued to Lind an aggregate of 698,630 shares of common stock to satisfy a $255,000 conversion obligation, (d) on August 31, 2026 the Company issued to Lind an aggregate of 695,890 shares of common stock to satisfy a $254,000 conversion obligation, (e) on August 31, 2026 the Company issued to Lind an aggregate of 693,151 shares of common stock to satisfy a $253,000 conversion obligation, (f) on August 31, 2026 the Company issued to Lind an aggregate of 690,411 shares of common stock to satisfy a $252,000 conversion obligation, and (g) on August 31, 2026 the Company issued to Lind an aggregate of 687,671 shares of common stock to satisfy a $251,000 conversion obligation. The offering and sale of the shares of common stock underlying the note was made in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506 of Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The issuance of the shares of common stock was to an existing securityholder, did not involve any paid commissions, did not involve a public offering and was made without general solicitation or general advertising.
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VOLITIONRX LIMITED |
| |
|
|
| |
Date: September 1, 2026 | By: | /s/ Cameron Reynolds |
|
|
| Cameron Reynolds |
|
|
| Chief Executive Officer & President |
|
| 3 |